We are monitoring the impact of COVID-19 on APAC Lung Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 836
Share on
Share on

Asia Pacific Lung Cancer Therapeutics Market Research Report - Segmented By Treatment Type & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 836
Pages: 141

APAC Lung Cancer Therapeutics Market Size (2021 to 2026)

The Asia-Pacific Lung Cancer Therapeutics Market is forecasted to worth USD 1.70 billion by 2026 and USD 1.17 billion in 2021, growing at a CAGR of 7.65% from 2021 to 2026. Asia-Pacific countries such as India and China are the developing regions for the global lung cancer therapeutics market due to the high occurrence of this disease and growing healthcare alertness.

The proliferation of lung cancer is primarily driving the APAC market growth. The most significant risk factor for lung cancer is cigarette smoking. Lung cancer can also be caused by prolonged exposure to cigarette smoke. Targeted therapy is a type of cancer treatment that differs from standard chemotherapy. The medicines used in target treatment operate by focusing on specific genes or proteins found in cancer cells. The other factor, such as increasing pollution due to rapid industrialization, is causing lung cancer risk, influencing the market growth. Patients with advanced illness, in particular, have a dismal prognosis, requiring the development of new treatment alternatives. As a result, the NSCLC market shifts away from generic chemotherapy regimens and toward a more complicated treatment landscape based on distinct NSCLC subtypes and molecular aberrations. Over half of all NSCLC cases are detected in those over 65, which is a high-risk age for lung cancer.

The growing awareness among the people about cancer therapeutics in developing countries such as China and India is propelling the market growth in this region. As the region's population ages, the prevalence of lung cancer is expected to rise, providing a revenue boost. An increase in the investment and funding and investments by government and private organizations on research and development of new drugs is expected to uplift the market growth.

Additionally, the adoption of new medical diagnostic Equipment and emerging therapeutics is most likely to increase the market growth. Therefore, the region's key market players focus on constant innovations and product up-gradation and efficient product offering for better treatments and outcomes for the patients.  

During the projected period, the immunotherapy sector is predicted to grow at a higher CAGR. The growing number of new product releases, particularly in the immunotherapy sector, is attributed to the market's rise. In addition, immunotherapy is becoming more popular in developing countries due to its more effective treatment, which leads to better patient outcomes.

However, the side effects of drug therapies and the high cost of the therapies have been restraining the market growth.

This research report on the APAC Lung Cancer Therapeutics Market is segmented and sub-segmented into the following categories:

By Treatment Type:

  • Chemotherapy
    • Cisplatin
    • Taxol
    • Navelbine
    • Camptosar
    • Alimta
  • Radiotherapy
    • External Beam
    • Internal Beam
    • Systemic
  • Other Drugs
    • Abraxane
    • Avastin
    • Crizotinib
    • Docetaxel
    • Gefitinib

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, the APAC is anticipated to account significant share in the global lung cancer therapeutics market. In addition, cigarette smoking has remained common in the Asia-Pacific region. As a result of the growing prevalence of cancer, the market is expected to rise throughout the forecast period. China is estimated to witness the highest share in the market in the forecast period in the regional market. Growing regulatory approvals and adopting advanced therapeutics are more likely to contribute to the highest share. The most prevalent cancers in China include lung, stomach, colorectum, liver, and esophagus. In addition, population expansion, age, environmental pollution, and bad eating habits contribute to an increase in cancer burden and, as a result, cancer treatments.

Also, the Japanese lung cancer therapeutics market is projected to contribute to the APAC regional market growth. New product launches and the prevalence of cancer are expected to escalate the market growth. In addition, the Japanese Ministry of Health, Labor, and Welfare (JMHLW) authorized Keytruda in December 2018 for new indications in advanced, recurrent, or unresectable NSCLC, malignant melanoma, and high microsatellite instability solid tumors. This would help to enhance the company's position in Japan.

The Indian lung cancer therapeutics market is one of the fastest-growing markets in the Asia Pacific over the forecast period. Favorable investments from the government and improving healthcare infrastructure are projected to increase the market growth. In India, F. Hoffmann-La Roche Ltd has introduced Tecentriq, a cancer treatment used for urothelial carcinoma and non-small cell lung cancer (NSCLC). The firm would be able to grow its market in India as a result of this.

KEY MARKET PLAYERS:

A few of the promising companies operating in the APAC Lung Cancer Therapeutics Market profiled in this report are Boehringer Ingelheim GmbH, Hoffman-La Roche, Pfizer Inc., GlaxoSmithKline, Eli Lilly and Company, Agennix AG, AstraZeneca plc, and Sanofi-Aventis.

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods                                           

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                              

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                            

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                     

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                      

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 New Developments                                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                      

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                               

5. Market Segmentation                                                              

                5.1 By Treatment Type                                 

                                5.1.1 Chemotherapy                     

                                                5.1.1.1 Cisplatin

                                                5.1.1.2 Taxol      

                                                5.1.1.3 Navelbine            

                                                5.1.1.4 Camptosar          

                                                5.1.1.5 Alimta   

                                5.1.2 Radiotherapy                         

                                                5.1.2.1 External Beam   

                                                5.1.2.2 Internal Beam    

                                                5.1.2.3 Systemic              

                                5.1.3 Other Drugs                            

                                                5.1.3.1 Abraxane             

                                                5.1.3.2 Avastin 

                                                5.1.3.3 Crizotinib             

                                                5.1.3.4 Docetaxel            

                                                5.1.3.5 Gefitinib               

6. Geographical Analysis                                                              

                6.1 Introduction                                              

                6.2 China                                            

                6.3 India                                              

                6.4 Japan                                            

                6.5 South Korea                               

                6.6 Australia                                      

7. Pipeline Product Analysis                                                       

                7.1 Overview                                                    

                7.2 Pipeline Development Landscape                                                    

                7.3 Molecular Targets in the Pipeline                                                     

                7.4 Clinical Trials                                             

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target                       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                                  

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.                               

8. Strategic Analysis                                                       

                8.1 PESTLE analysis                                         

                                8.1.1 Political                     

                                8.1.2 Economic                 

                                8.1.3 Social                         

                                8.1.4 Technological                         

                                8.1.5 Legal                          

                                8.1.6 Environmental                      

                8.2 Porter’s Five analysis                                              

                                8.2.1 Bargaining Power of Suppliers                        

                                8.2.2 Bargaining Power of Consumers                    

                                8.2.3 Threat of New Entrants                     

                                8.2.4 Threat of Substitute Products and Services               

                                8.2.5 Competitive Rivalry within the Industry                      

9. Market Leaders' Analysis                                                        

                9.1 BoehringerIngelheim GmbH                               

                                9.1.1 Overview                

                                9.1.2 Product Analysis                   

                                9.1.3 Strategic Evaluation and Operations                            

                                9.1.4 Financial analysis                  

                                9.1.5 Legal issues                            

                                9.1.6 Recent Developments                       

                                9.1.7 SWOT analysis                       

                                9.1.8 Analyst View                          

                9.2 Hoffman-La Roche                                  

                9.3 Pfizer Inc.                                    

                9.4 GlaxoSmitKline                                         

                9.5 Eli Lilly and Company                                             

                9.6 AstrazenecaPlc                                         

                9.7 Sanofi-Aventis                                          

                9.8 Agennix AG                                

10. Competitive Landscape                                                         

                10.1 Market share analysis                                          

                10.2 Merger and Acquisition Analysis                                     

                10.3 Agreements, collaborations and Joint Ventures                                       

                10.4 New Product Launches                                       

11. Expert Opinions                                                        

                11.1 Market Outlook                                     

                11.2 Investment Opportunities                                 

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Lung Cancer Therapeutics Market, By Region, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Chemotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Radiotherapy Market, By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Other Lung Cancer Therapeutic Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  6. China Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  7. India Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  8. Japan Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  9. South Korea Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  10. Australia Lung Cancer Therapeutics Market, By Treatment Type, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Cisplatin Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Taxol Market, By Region, From 2021 to 2026 (USD Billion)
  14. Asia-Pacific Navelbine Market, By Region, From 2021 to 2026 (USD Billion)
  15. Asia-Pacific Camptosar Market, By Region, From 2021 to 2026 (USD Billion)
  16. Asia-Pacific Alimta Market, By Region, From 2021 to 2026 (USD Billion)
  17. China Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  18. India Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  19. Japan Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  20. South Korea Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  21. Australia Lung Cancer Chemotherapy Market, By Drug Type, From 2021 to 2026 (USD Billion)
  22. Asia-Pacific Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  23. Asia-Pacific External Beam Market, By Region, From 2021 to 2026 (USD Billion)
  24. Asia-Pacific Internal Beam Market, By Region, From 2021 to 2026 (USD Billion)
  25. Asia-Pacific Systemic Market, By Region, From 2021 to 2026 (USD Billion)
  26. China Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  27. India Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  28. Japan Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  29. South Korea Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  30. Australia Lung Cancer Radiotherapy Market, By Type, From 2021 to 2026 (USD Billion)
  31. Asia-Pacific Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  32. Asia-Pacific Abraxane Market, By Region, From 2021 to 2026 (USD Billion)
  33. Asia-Pacific Avastin Market, By Region, From 2021 to 2026 (USD Billion)
  34. Asia-Pacific Crizotinib Market, By Region, From 2021 to 2026 (USD Billion)
  35. Asia-Pacific Docetaxel Market, By Region, From 2021 to 2026 (USD Billion)
  36. Asia-Pacific Gefitinib Market, By Region, From 2021 to 2026 (USD Billion)
  37. China Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  38. India Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  39. Japan Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  40. South Korea Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)
  41. Australia Other Lung Cancer Therapeutic Drugs Market, By Drug Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample